Claims
- 1. A method for treating or preventing thrombosis in a subject, comprising:
identifying a subject at risk for high shear-induced thrombosis; and administrating to the subject a CD154 inhibitor in an amount effective to inhibit the release of soluble CD154 (sCD154) from a platelet, to thereby treat the subject.
- 2. The method of claim 1, wherein the subject at risk for high shear rate-induced thrombosis is a subject that has a pre-existing narrowing of a blood vessel.
- 3. The method of claim 2, wherein the subject has a pre-existing cardiovascular disease.
- 4. The method of claim 2, wherein the subject has undergone a procedure which can induce restenosis.
- 5. The method of claim 4, wherein the subject has undergone a procedure selected from the group consisting of: percutaneous coronary intervention (PCI), PCTA, stent implantation, cardiac-pulmonary by-pass surgery and coronary revascularization surgery.
- 6. The method of claim 3, wherein the subject has unstable angina.
- 7. The method of claim 1, further comprising administering one or more additional therapeutic agents selected from the group consisting of: an anti-inflammatory agent, a thrombolytic agent, a cholesterol lowering agent, a blood pressure lowering agent and an anti-coagulant.
- 8. The method of claim 1, further comprising administering an anti-coagulant wherein the anticoagulant is selected from the group consisting of a thrombin inhibitor, coumadin, warfarin or a heparin.
- 9. A method for treating a subject having an impaired immune response, comprising:
administering to the subject a platelet aggregation inhibitor at a dose effective to result in a proinflammory response in the subject, to thereby treat the subject.
- 10. The method of claim 9, wherein the effective dose of the platelet aggregation inhibitor is a dose which inhibits platelet aggregation by less than 50%.
- 11. The method of claim 9, wherein the effective dose of the platelet aggregation inhibitor is a dose which inhibits platelet aggregation by less than 30%.
- 12. The method of claim 9, wherein the platelet aggregation inhibitor is selected from the group consisting of eptifibatide, abciximab, tirofiban, sibrafib an, xemilo fib an, orbo fib an, lotrafiban, aggrastat, and a disintegrin.
- 13. The method of claim 9, wherein the platelet aggregation inhibitor is eptifibatide and the eptifibatide is administered at a dose less than 2.0 μmoles/L.
- 14. The method of claim 13, wherein the eptifibatide is administered at a dose less than 1.0 μmoles/L.
- 15. The method of claim 9, wherein the platelet aggregation inhibitor is eptifibatide and the eptifibatide is administered over a period of time at a rate of 0.9 μg/kg/minute or less.
- 16. The method of claim 15, wherein the eptifibatide is administered over a period of time at a rate of 0.7 μg/kg/minute or less.
- 17. The method of claim 15 or 16, wherein the eptifibatide is administered over a period of at least 10 hours or more.
- 18. The method of claim 9, wherein the platelet aggregation inhibitor is administered by a route of administration which results in platelet aggregation being inhibited by less than 50%.
- 19. The method of claim 18, wherein the platelet aggregation inhibitor is administered by oral administration.
- 20. The method of claim 9, wherein the effective dose is a dose which results in an increase in sCD154 release by at least 15% as compared to a reference standard.
- 21. The method of claim 20, wherein the reference standard is based upon the level of sCD154 release at a dosage of about 2.5 μmole/L of eptifibatide.
RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S. Ser. No.: ______, filed Feb. 17, 2003 which is a continuation-in-part of PCT Application Number PCT/US02/13900, filed May 3, 2002, which is a continuation of U.S. application Ser. No. 10/002,585, filed Nov. 30, 2001 and claims the benefit of priority under 35 U.S.C. §119(e) to U.S. Provisional Application No. 60/289,049 filed on May 3, 2001, the contents of which are incorporated herein by reference in their entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60289049 |
May 2001 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
10002585 |
Nov 2001 |
US |
Child |
PCT/US02/13900 |
May 2002 |
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
10368947 |
Feb 2003 |
US |
Child |
10376425 |
Feb 2003 |
US |
Parent |
PCT/US02/13900 |
May 2002 |
US |
Child |
10368947 |
Feb 2003 |
US |